{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:41:24Z","timestamp":1770957684004,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,19]]},"DOI":"10.7759\/cureus.25129","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T07:42:06Z","timestamp":1652946126000},"source":"Crossref","is-referenced-by-count":1,"title":["Rituximab in Refractory Myositis and Acute Neuropathy Secondary to Checkpoint Inhibitor Therapy"],"prefix":"10.7759","author":[{"given":"Varun","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Remley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyra","family":"Bunag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisha","family":"Elfasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Chuquilin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar V","year":"2017","unstructured":"Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017, 8:49. 10.3389\/fphar.2017.00049","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo S","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, et al.. neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017, 73:1-8. 10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei SC","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018, 8:1069-86. 10.1158\/2159-8290.CD-18-0367","journal-title":"Cancer Discov"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/471561a","article-title":"Melanoma drug wins US approval","volume":"471","author":"Ledford H","year":"2011","unstructured":"Ledford H. Melanoma drug wins US approval. Nature. 2011, 471:561. 10.1038\/471561a","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-018-0571-8","article-title":"[Neurological side effects of checkpoint inhibitors]","volume":"90","author":"Knauss S","year":"2019","unstructured":"Knauss S, Ginesta Roque L, H\u00fchnchen P, Heinzerling L, B\u00f6hmerle W, Endres M. [Neurological side effects of checkpoint inhibitors]. Nervenarzt. 2019, 90:138-47. 10.1007\/s00115-018-0571-8","journal-title":"Nervenarzt"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain L","year":"2017","unstructured":"Spain L, Walls G, Julve M, et al.. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2017, 28:377-85. 10.1093\/annonc\/mdw558","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7886","article-title":"Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma","volume":"30","author":"Maur M","year":"2012","unstructured":"Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol. 2012, 30:e76-8. 10.1200\/JCO.2011.38.7886","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson DB","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, et al.. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019, 7:134. 10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16337","article-title":"Rituximab for immune checkpoint inhibitor myasthenia gravis","volume":"13","author":"Verma N","year":"2021","unstructured":"Verma N, Jaffer M, Pina Y, Peguero E, Mokhtari S. Rituximab for immune checkpoint inhibitor myasthenia gravis. Cureus. 2021, 13:e16337. 10.7759\/cureus.16337","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.001","article-title":"Effectiveness of rituximab in treating immune-checkpoint-inhibitor-induced immune-related adverse events: results of a systematic review","volume":"32","author":"Deftereos SN","year":"2021","unstructured":"Deftereos SN, Georgonikou D. Effectiveness of rituximab in treating immune-checkpoint-inhibitor-induced immune-related adverse events: results of a systematic review. Ann Oncol. 2021, 32:282-3. 10.1016\/j.annonc.2020.12.001","journal-title":"Ann Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/95996-rituximab-in-refractory-myositis-and-acute-neuropathy-secondary-to-checkpoint-inhibitor-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:43:37Z","timestamp":1707507817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/95996-rituximab-in-refractory-myositis-and-acute-neuropathy-secondary-to-checkpoint-inhibitor-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.25129","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,19]]}}}